CEO sold ~$1.77M of Gilead Sciences
Scheduled in advanceLoading…
Chairman & CEO
Disclosures on record
49
Companies involved
1
CEO sold ~$1.77M of Gilead Sciences
Scheduled in advanceCEO sold ~$446K of Gilead Sciences
Scheduled in advanceDerivative exercise or conversion — not an open-market buy.
Derivative exercise or conversion — not an open-market buy.
Routine share withholding; mechanical by default.
CEO sold ~$1.19M of Gilead Sciences
Scheduled in advanceCEO sold ~$808K of Gilead Sciences
Scheduled in advanceCEO sold ~$236K of Gilead Sciences
Scheduled in advanceCEO sold ~$1.01M of Gilead Sciences
Scheduled in advanceCEO sold ~$869K of Gilead Sciences
Scheduled in advanceCEO sold ~$79K of Gilead Sciences
Scheduled in advanceCEO sold ~$1.5M of Gilead Sciences
Scheduled in advanceCEO sold ~$394K of Gilead Sciences
Scheduled in advanceDerivative exercise or conversion — not an open-market buy.
Derivative exercise or conversion — not an open-market buy.
Routine share withholding; mechanical by default.
CEO sold ~$1.43M of Gilead Sciences
Scheduled in advanceCEO sold ~$405K of Gilead Sciences
Scheduled in advanceCEO sold ~$138K of Gilead Sciences
Scheduled in advanceCEO sold ~$895K of Gilead Sciences
Scheduled in advanceCEO sold ~$397K of Gilead Sciences
Scheduled in advanceCEO sold ~$1.37M of Gilead Sciences
Scheduled in advanceCompensation award — excluded from discretionary-purchase analysis.
Compensation award — excluded from discretionary-purchase analysis.
Derivative exercise or conversion — not an open-market buy.
Derivative exercise or conversion — not an open-market buy.
Routine share withholding; mechanical by default.
CEO sold ~$932K of Gilead Sciences
Scheduled in advanceCEO sold ~$501K of Gilead Sciences
Scheduled in advanceCEO sold ~$15K of Gilead Sciences
Scheduled in advanceCompensation award — excluded from discretionary-purchase analysis.
CEO sold ~$17.3M of Gilead Sciences
Scheduled in advanceDerivative exercise or conversion — not an open-market buy.
Derivative exercise or conversion — not an open-market buy.
Compensation award — excluded from discretionary-purchase analysis.
Routine share withholding; mechanical by default.
CEO sold ~$702K of Gilead Sciences
Scheduled in advanceCEO sold ~$697K of Gilead Sciences
Scheduled in advanceCEO sold ~$15.6M of Gilead Sciences
Scheduled in advanceDerivative exercise or conversion — not an open-market buy.
Derivative exercise or conversion — not an open-market buy.
CEO sold ~$1.25M of Gilead Sciences
Scheduled in advanceDerivative exercise or conversion — not an open-market buy.
Derivative exercise or conversion — not an open-market buy.
Routine share withholding; mechanical by default.
CEO sold ~$861K of Gilead Sciences
Scheduled in advanceCEO sold ~$404K of Gilead Sciences
Scheduled in advanceCEO sold ~$954K of Gilead Sciences
Scheduled in advanceCEO sold ~$240K of Gilead Sciences
Scheduled in advance